Piroxicam side effects: what 6,344 FDA adverse event reports show
Drug class
Nonsteroidal Anti-inflammatory Drug
Who reports
6,344 reports · 84% serious · 1,103 with death outcome · 71% female
Used for
Piroxicam Capsules are a nonsteroidal anti-inflammatory drug indicated for Relief of the signs and symptoms of osteoarthritis (OA) (1) Relief of the signs and symptoms of rheumatoid arthritis (RA) (1) Piroxicam Capsules are indicated: For relief of the signs and symptoms of osteoarthritis. For relief of the signs and symptoms of rheumatoid arthritis.
What it is
Piroxicam Capsules USP is a nonsteroidal anti-inflammatory drug, available as maroon and blue #10 mg capsules and maroon #20 mg capsules for oral administration.
Boxed warning
RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning . Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 591 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Helicobacter infection | 498 | 169.8 155.7–185.1ROR 184.1 · χ² 79,292 / p <1e-300 | 160.4 EB05 148.9 · IC025 +7.0 3/3 methods agree | Not in label — unassessed | serious PRR 117.5 · ♀ 100% (drug 71%) · 94% clinician | not reported in cached trials |
| Sciatica | 772 | 169.1 158.0–181.0ROR 192.4 · χ² 122,603 / p <1e-300 | 160.2 EB05 150.9 · IC025 +7.1 3/3 methods agree | Not in label — unassessed | serious PRR 148.4 · ♀ 99% (drug 71%) · 91% clinician | not reported in cached trials |
| Folliculitis | 480 | 161.1 147.5–176.0ROR 174.2 · χ² 72,651 / p <1e-300 | 152.6 EB05 141.5 · IC025 +6.9 3/3 methods agree | Not in label — unassessed | serious PRR 124.4 · ♀ 100% (drug 71%) · 95% clinician | not reported in cached trials |
| Autoimmune disorder | 430 | 155.5 141.6–170.7ROR 166.7 · χ² 62,874 / p <1e-300 | 147.5 EB05 136.1 · IC025 +6.8 3/3 methods agree | Not in label — unassessed | serious PRR 109.4 · ♀ 100% (drug 71%) · 94% clinician | not reported in cached trials |
| Pemphigus | 500 | 138.5 127.1–150.9ROR 150.3 · χ² 65,379 / p <1e-300 | 132.2 EB05 122.8 · IC025 +6.7 3/3 methods agree | Not in label — unassessed | serious PRR 91.8 · ♀ 99% (drug 71%) · 94% clinician | not reported in cached trials |
| Hand deformity | 507 | 133.2 122.3–145.1ROR 144.7 · χ² 63,842 / p <1e-300 | 127.4 EB05 118.4 · IC025 +6.7 3/3 methods agree | Not in label — unassessed | serious PRR 96.0 · ♀ 100% (drug 71%) · 96% clinician | not reported in cached trials |
| Bursitis | 393 | 111.3 100.9–122.7ROR 118.6 · χ² 41,447 / p <1e-300 | 107.1 EB05 98.5 · IC025 +6.4 3/3 methods agree | Not in label — unassessed | serious PRR 87.1 · ♀ 100% (drug 71%) · 94% clinician | not reported in cached trials |
| Pericarditis | 494 | 101.0 92.6–110.0ROR 109.4 · χ² 47,362 / p <1e-300 | 97.6 EB05 90.6 · IC025 +6.3 3/3 methods agree | Not in label — unassessed | serious PRR 68.0 · ♀ 100% (drug 71%) · 94% clinician | not reported in cached trials |
| Synovitis | 523 | 98.6 90.7–107.2ROR 107.4 · χ² 49,003 / p <1e-300 | 95.4 EB05 88.8 · IC025 +6.3 3/3 methods agree | Not in label — unassessed | serious PRR 69.0 · ♀ 99% (drug 71%) · 94% clinician | not reported in cached trials |
| Wound infection | 309 | 96.7 86.6–108.0ROR 101.6 · χ² 28,344 / p <1e-300 | 93.4 EB05 85.0 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious PRR 69.4 · ♀ 99% (drug 71%) · 92% clinician | not reported in cached trials |
| Joint range of motion decreased | 364 | 92.5 83.6–102.4ROR 98.1 · χ² 31,972 / p <1e-300 | 89.6 EB05 82.1 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious PRR 79.1 · ♀ 95% (drug 71%) · 93% clinician | not reported in cached trials |
| Lower limb fracture | 462 | 81.9 75.0–89.6ROR 88.3 · χ² 35,983 / p <1e-300 | 79.7 EB05 73.8 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious PRR 60.5 · ♀ 100% (drug 71%) · 93% clinician | not reported in cached trials |
| Glossodynia (burning tongue/mouth pain) | 494 | 74.7 68.5–81.4ROR 80.9 · χ² 35,066 / p <1e-300 | 72.8 EB05 67.6 · IC025 +5.9 3/3 methods agree | Labeled (related wording) related wording | serious PRR 72.4 · ♀ 100% (drug 71%) · 95% clinician | not reported in cached trials |
| Red blood cell sedimentation rate increased | 240 | 73.1 64.5–82.9ROR 75.9 · χ² 16,628 / p <1e-300 | 71.1 EB05 63.9 · IC025 +5.7 3/3 methods agree | Lab value / disease marker | serious PRR 55.9 · ♀ 99% (drug 71%) | not reported in cached trials |
| Fibromyalgia | 514 | 71.4 65.7–77.7ROR 77.7 · χ² 34,908 / p <1e-300 | 69.8 EB05 64.8 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious PRR 63.2 · ♀ 100% (drug 71%) · 94% clinician | not reported in cached trials |
| Obesity | 330 | 69.8 62.8–77.6ROR 73.6 · χ² 21,854 / p <1e-300 | 68.1 EB05 62.1 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious PRR 54.3 · ♀ 98% (drug 71%) | not reported in cached trials |
| Wound | 572 | 69.4 64.1–75.1ROR 76.2 · χ² 37,746 / p <1e-300 | 67.8 EB05 63.3 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious PRR 55.6 · ♀ 100% (drug 71%) · 91% clinician | not reported in cached trials |
| Liver injury | 495 | 69.1 63.4–75.2ROR 74.8 · χ² 32,482 / p <1e-300 | 67.5 EB05 62.6 · IC025 +5.8 3/3 methods agree | Labeled (related wording) related wording | serious PRR 48.3 · ♀ 100% (drug 71%) · 94% clinician | not reported in cached trials |
| Psoriatic arthropathy | 820 | 68.8 64.5–73.4ROR 78.8 · χ² 53,675 / p <1e-300 | 67.3 EB05 63.5 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious PRR 58.3 · ♀ 97% (drug 71%) · 91% clinician | not reported in cached trials |
| Irritable bowel syndrome | 430 | 67.9 61.9–74.4ROR 72.7 · χ² 27,714 / p <1e-300 | 66.3 EB05 61.2 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious PRR 58.1 · ♀ 100% (drug 71%) · 95% clinician | not reported in cached trials |
| Hypercholesterolaemia | 191 | 67.3 58.4–77.5ROR 69.4 · χ² 12,164 / p <1e-300 | 65.6 EB05 58.1 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious PRR 48.3 · ♀ 98% (drug 71%) · 93% clinician | not reported in cached trials |
| Prescribed overdose | 325 | 56.4 50.7–62.8ROR 59.4 · χ² 17,359 / p <1e-300 | 55.3 EB05 50.5 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious PRR 65.0 · ♀ 99% (drug 71%) · 92% clinician | not reported in cached trials |
| Type 2 diabetes mellitus | 534 | 53.1 48.9–57.6ROR 57.9 · χ² 26,843 / p <1e-300 | 52.2 EB05 48.5 · IC025 +5.5 3/3 methods agree | Labeled (related wording) related wording | serious PRR 37.5 · ♀ 98% (drug 71%) · 92% clinician | not reported in cached trials |
| Pulmonary fibrosis | 297 | 52.2 46.6–58.3ROR 54.7 · χ² 14,631 / p <1e-300 | 51.2 EB05 46.5 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious PRR 35.8 · ♀ 99% (drug 71%) · 96% clinician | not reported in cached trials |
| Hip arthroplasty | 226 | 49.9 43.9–56.8ROR 51.7 · χ² 10,630 / p <1e-300 | 49.0 EB05 43.9 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious PRR 34.8 · ♀ 96% (drug 71%) · 91% clinician | not reported in cached trials |
| Contraindicated product administered | 442 | 49.1 44.9–53.8ROR 52.7 · χ² 20,517 / p <1e-300 | 48.3 EB05 44.7 · IC025 +5.4 3/3 methods agree | Reporting / coding artifact | serious PRR 41.4 · ♀ 99% (drug 71%) | not reported in cached trials |
| Systemic lupus erythematosus | 517 | 49.0 45.1–53.3ROR 53.3 · χ² 23,946 / p <1e-300 | 48.2 EB05 44.8 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious PRR 34.1 · ♀ 100% (drug 71%) · 94% clinician | not reported in cached trials |
| Impaired healing | 468 | 47.8 43.8–52.2ROR 51.5 · χ² 21,109 / p <1e-300 | 47.0 EB05 43.5 · IC025 +5.3 3/3 methods agree | Reporting / coding artifact | serious PRR 39.0 · ♀ 99% (drug 71%) · 91% clinician | not reported in cached trials |
| Laryngitis | 149 | 46.0 39.2–53.9ROR 47.1 · χ² 6,423 / p <1e-300 | 45.1 EB05 39.3 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=148 · ♀ 100% (drug 71%) · 97% clinician | not reported in cached trials |
| Foot deformity | 144 | 43.4 36.9–51.1ROR 44.4 · χ² 5,853 / p <1e-300 | 42.7 EB05 37.1 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 33.6 · ♀ 98% (drug 71%) · 95% clinician | not reported in cached trials |
| Night sweats | 392 | 40.7 37.0–44.8ROR 43.3 · χ² 14,985 / p <1e-300 | 40.2 EB05 36.9 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious PRR 47.4 · ♀ 99% (drug 71%) · 93% clinician | not reported in cached trials |
| Blood cholesterol increased | 559 | 40.1 37.0–43.4ROR 43.9 · χ² 21,052 / p <1e-300 | 39.6 EB05 36.9 · IC025 +5.1 3/3 methods agree | Lab value / disease marker | serious PRR 41.0 · ♀ 98% (drug 71%) · 94% clinician | not reported in cached trials |
| Prescribed underdose | 234 | 39.2 34.6–44.5ROR 40.7 · χ² 8,583 / p <1e-300 | 38.7 EB05 34.7 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious PRR 45.7 · ♀ 99% (drug 71%) | not reported in cached trials |
| Arthropathy | 632 | 37.9 35.1–40.8ROR 41.9 · χ² 22,445 / p <1e-300 | 37.4 EB05 35.0 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious PRR 31.3 · ♀ 97% (drug 71%) · 92% clinician | not reported in cached trials |
| Joint dislocation | 116 | 36.8 30.7–44.1ROR 37.5 · χ² 3,962 / p <1e-300 | 36.2 EB05 31.0 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious PRR 28.0 · ♀ 97% (drug 71%) · 90% clinician | not reported in cached trials |
| Osteoarthritis | 467 | 36.7 33.6–40.1ROR 39.6 · χ² 16,049 / p <1e-300 | 36.3 EB05 33.6 · IC025 +5.0 3/3 methods agree | Likely indication confounding term in indications | serious PRR 27.9 · ♀ 94% (drug 71%) | not reported in cached trials |
| Pregnancy | 221 | 36.5 32.0–41.6ROR 37.8 · χ² 7,518 / p <1e-300 | 36.0 EB05 32.2 · IC025 +4.8 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 36.4 · ♀ 100% (drug 71%) · 97% clinician | not reported in cached trials |
| Road traffic accident | 454 | 36.2 33.1–39.6ROR 38.9 · χ² 15,377 / p <1e-300 | 35.8 EB05 33.1 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 28.6 · ♀ 99% (drug 71%) · 91% clinician | not reported in cached trials |
| Knee arthroplasty | 223 | 35.7 31.4–40.7ROR 37.0 · χ² 7,417 / p <1e-300 | 35.2 EB05 31.5 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious PRR 25.4 · ♀ 99% (drug 71%) | not reported in cached trials |
| Gait inability | 353 | 35.6 32.2–39.4ROR 37.7 · χ² 11,732 / p <1e-300 | 35.2 EB05 32.2 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious PRR 30.1 · ♀ 100% (drug 71%) · 93% clinician | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Piroxicam as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT03614494 — Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception (N=860, PHASE2, PHASE3; 7 AE terms posted; arms: Piroxicam; Placebo)
- NCT02450487 — Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar (N=105, PHASE4; 2 AE terms posted; arms: Interventional Group)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 979 | 16.7 15.8–17.7ROR 19.6 · χ² 14,533 / p <1e-300 | 16.7 EB05 15.8 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious PRR 28.4 · ♀ 96% (drug 71%) · 91% clinician | not reported in cached trials |
| Rash | 921 | 7.0 6.6–7.5ROR 8.1 · χ² 4,850 / p <1e-300 | 7.0 EB05 6.6 · IC025 +2.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 10.3 · ♀ 95% (drug 71%) | not reported in cached trials |
| Arthralgia (joint pain) | 915 | 7.3 6.9–7.8ROR 8.4 · χ² 5,068 / p <1e-300 | 7.3 EB05 6.9 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious PRR 8.8 | not reported in cached trials |
| Condition aggravated | 908 | 10.0 9.4–10.6ROR 11.5 · χ² 7,399 / p <1e-300 | 9.9 EB05 9.4 · IC025 +3.2 3/3 methods agree | Reporting / coding artifact | serious PRR 10.2 · ♀ 93% (drug 71%) | not reported in cached trials |
| Drug ineffective (drug did not work) | 868 | 2.2 2.0–2.3ROR 2.4 · χ² 590 / p 2e-130 | 2.2 EB05 2.1 · IC025 +1.0 3/3 methods agree | Reporting / coding artifact | serious PRR 3.8 | not reported in cached trials |
| Fatigue (tiredness) | 856 | 3.6 3.4–3.9ROR 4.1 · χ² 1,701 / p <1e-300 | 3.6 EB05 3.4 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 4.4 | NCT03614494: 43/418 (10.3%) on Piroxicam; 52/418 (12.4%) control |
| Rheumatoid arthritis | 856 | 25.2 23.7–26.8ROR 29.0 · χ² 19,827 / p <1e-300 | 25.0 EB05 23.6 · IC025 +4.5 3/3 methods agree | Likely indication confounding term in indications | serious PRR 20.9 · ♀ 96% (drug 71%) | not reported in cached trials |
| Diarrhoea (diarrhea) | 846 | 4.4 4.1–4.6ROR 4.9 · χ² 2,246 / p <1e-300 | 4.3 EB05 4.1 · IC025 +2.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 5.1 · ♀ 93% (drug 71%) | not reported in cached trials |
| Pain | 843 | 4.5 4.3–4.8ROR 5.1 · χ² 2,384 / p <1e-300 | 4.5 EB05 4.3 · IC025 +2.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 4.6 | NCT03614494: 31/418 (7.4%) on Piroxicam; 29/418 (6.9%) control |
| Nausea | 825 | 3.5 3.2–3.7ROR 3.8 · χ² 1,494 / p <1e-300 | 3.5 EB05 3.3 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 4.3 · ♀ 92% (drug 71%) | NCT03614494: 32/418 (7.7%) on Piroxicam; 34/418 (8.1%) control |
| Psoriatic arthropathy | 820 | 68.8 64.5–73.4ROR 78.8 · χ² 53,675 / p <1e-300 | 67.3 EB05 63.5 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious PRR 58.3 · ♀ 97% (drug 71%) · 91% clinician | not reported in cached trials |
| Sinusitis | 809 | 26.2 24.6–28.0ROR 29.9 · χ² 19,533 / p <1e-300 | 26.0 EB05 24.5 · IC025 +4.6 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 35.4 · ♀ 98% (drug 71%) · 91% clinician | not reported in cached trials |
| Sciatica | 772 | 169.1 158.0–181.0ROR 192.4 · χ² 122,603 / p <1e-300 | 160.2 EB05 150.9 · IC025 +7.1 3/3 methods agree | Not in label — unassessed | serious PRR 148.4 · ♀ 99% (drug 71%) · 91% clinician | not reported in cached trials |
| Off label use (used outside approved label) | 768 | 2.9 2.7–3.1ROR 3.2 · χ² 1,013 / p 1e-222 | 2.9 EB05 2.8 · IC025 +1.4 3/3 methods agree | Reporting / coding artifact | serious PRR 3.6 · ♀ 95% (drug 71%) | not reported in cached trials |
| Headache | 750 | 4.0 3.7–4.2ROR 4.4 · χ² 1,707 / p <1e-300 | 3.9 EB05 3.7 · IC025 +1.9 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 5.3 | NCT03614494: 21/418 (5.0%) on Piroxicam; 27/418 (6.5%) control |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Helicobacter infection — n=498, PRR 169.8
- Sciatica — n=772, PRR 169.1
- Folliculitis — n=480, PRR 161.1
- Autoimmune disorder — n=430, PRR 155.5
- Pemphigus — n=500, PRR 138.5
- Hand deformity — n=507, PRR 133.2
- Bursitis — n=393, PRR 111.3
- Pericarditis — n=494, PRR 101.0
- Synovitis — n=523, PRR 98.6
- Wound infection — n=309, PRR 96.7
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Piroxicam?
In FDA FAERS, the most frequently co-reported reaction terms for Piroxicam are drug hypersensitivity, rash, arthralgia, fatigue, rheumatoid arthritis, diarrhoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Piroxicam have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning . Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
Do FAERS signals prove that Piroxicam causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 6039e036-c0aa-4249-af50-115f49ad758a, effective 20250806; matched on
openfda.generic_name.exact:"PIROXICAM") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 631 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
PIROXICAM, results-bearing studies sorted by enrollment)
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.